De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

Abstract Androgen receptor splice variant‐7 (AR‐V7), one of the major driving factors, is the most attractive drug target in castration‐resistant prostate cancer (CRPC). Currently, no available drugs efficiently target AR‐V7 in clinical practice. The DNA binding domain (DBD) is indispensable for the...

Full description

Bibliographic Details
Main Authors: Bohan Ma, Yizeng Fan, Dize Zhang, Yi Wei, Yanlin Jian, Donghua Liu, Zixi Wang, Yang Gao, Jian Ma, Yule Chen, Shan Xu, Lei Li
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Advanced Science
Subjects:
androgen receptor splice variant‐7 (AR‐V7)
peptide drug
prostate cancer
proteolysis‐targeting chimera (PROTAC)
Online Access:https://doi.org/10.1002/advs.202201859

Internet

https://doi.org/10.1002/advs.202201859

Similar Items